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Abstract 
Almost a century ago the first clinical account of the ‘punch drunk’ syndrome 
emerged, describing chronic neurologic and neuropsychiatric sequelae in former 
boxers. Thereafter, throughout the 20th century, further reports added to our 
understanding of the neuropathological consequences of a career in boxing, leading 
to descriptions of a distinct neurodegenerative pathology termed dementia 
pugilistica. In the past decade, growing recognition of this pathology in autopsy 
studies in non-boxers exposed to repetitive mild traumatic brain injury (TBI) or to 
single moderate or severe TBI has led to an awareness that it is exposure to TBI that 
carries with it risk of this neurodegenerative disease, not the sport or circumstance in 
which the injury is sustained. Furthermore, the neuropathology of this post-TBI 
neurodegeneration, now termed chronic traumatic encephalopathy, is acknowledged 
as a complex, mixed, but distinctive pathology, the detail of which is reviewed in this 
article.  
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Introduction 
Traumatic brain injury (TBI) represents a leading cause of morbidity and mortality 
internationally. In the United States alone, there are upwards of 2.5 million TBIs 
annually, with just under 300,000 requiring hospitalization and approximately 2% of 
the US population (approximately 5 million citizens) living with long-term disabilities 
as a consequence of TBI (1-4). As a result, the estimated annual TBI associated 
healthcare cost in the US is in excess of $60 billion (5).  Nevertheless, the evolving 
neuropathologies of TBI survival remain poorly described.  In particular, the 
association of a history of TBI with neurodegenerative disease has, thus far, been 
based on observations from limited cases series, often with incomplete 
clinicopathological correlation. As such, recognition of TBI-associated 
neurodegeneration in clinic and at autopsy is comparatively rare, with the 
consequence that the true prevalence and socioeconomic burden of these late TBI 
outcomes remain unknown.  
 
In his observations on the ‘punch drunk’ syndrome in former boxers almost 90 years 
ago the New Jersey Medical Examiner, Harrison S Martland, described a 
constellation of neuropsychiatric and motor symptoms, together with limited autopsy 
data, observing: 
‘The condition can no longer be ignored by the medical profession or the 
public. It is the duty of our profession to establish the existence or 
nonexistence of punch drunk by preparing accurate statistical data as to its 
incidence, careful neurologic examinations of fighters thought to be punch 
drunk, and careful histologic examinations of the brains of those who have 
died with symptoms….’(6) 
Thereafter, through the twentieth century, reports on further isolated case 
descriptions and short case series (7-10) reinforced Martland’s observations on the 
association between exposure to repetitive TBI in boxing and late neurodegenerative 
disease, with a distinct neuropathology later recognized and termed ‘dementia 
pugilistica’ (DP)(7). Perhaps since this condition was thought restricted to the 
uniquely brutal sport of boxing, DP garnered remarkably little interest, certainly not 
the formal studies called for by Martland to establish incidence and describe the 
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detailed neuropathology. However, in the last decade or so, with growing recognition 
of the neuropathology of DP in non-boxer athletes (11-20), and in survivors of single 
moderate or severe TBI (21-25), there is increasing acknowledgment that it is brain 
injury per se that is associated with risk of late neurodegenerative disease, rather 
than it being a unique consequence of participation in a single sport. Hence, the 
current, more encompassing term ‘chronic traumatic encephalopathy’ (CTE) was 
introduced. 
 
Inevitably, as reports of CTE have emerged in the media and in peer reviewed 
manuscripts attributed to a growing list of circumstances, in particular sports, there 
has been growing public concern. However, though almost 9 decades on from 
Martland’s first descriptions, we remain little further forward in understanding the true 
prevalence of CTE, with remarkably few cases described. Further, no robust and 
validated operational criteria for clinical diagnosis of CTE have been defined. At 
present, the diagnosis of CTE rests with neuropathological assessment at autopsy. 
Although, again, validated operational criteria are in their infancy, and the complex of 
pathologies contributing to CTE continues to be expanded.  This review describes 
our current understanding of the range of pathologies in survivors of TBI, and the 
potential pathological substrates linking TBI to this late neurodegeneration.  
 
Traumatic brain injury and dementia  
Traumatic brain injury is widely accepted as the strongest environmental risk factor 
for dementia (26-35). Indeed, not only is there evidence of a link between TBI and 
dementia, there is also evidence in support of a “dose response” relationship, with 
risk of dementia increased in severe versus moderate or mild TBI (34). However, 
much of the evidence supporting an association between TBI and later development 
of neurodegenerative disease comes from observational and retrospective studies, 
so may be influenced by recall bias. Best current estimates suggest a figure of 
between 5 to 15% of current dementia may be TBI related (36), representing in 
excess of 675,000 dementia patients in the US. However, as our appreciation of this 
link grows and appropriately designed prospective studies report, these figures 
undoubtedly will be revised.  
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Both historically and currently, TBI-associated dementia has been subdivided based 
on whether it follows single moderate or severe TBI (sTBI) or repetitive mild (rTBI) 
injury, with the associated clinical syndromes considered distinct. In particular, 
despite compelling literature to the contrary, there is a general presumption that 
“CTE” is limited to patients exposed to rTBI, most often athletes. This misperception 
may be due in part to a complete absence of comparative research or 
clinicopathological studies looking at material from both sTBI and rTBI patients in 
parallel. As such, consideration of late neurodegenerative outcomes from sTBI and 
rTBI as different syndromes is at best premature and, arguably, flawed. 
 
Following Martland’s seminal account of the ‘punch drunk’ syndrome describing 
chronic neuropsychiatric sequelae and limited associated pathology in former boxers 
(6), multiple other reports followed expanding on his findings. Of these, perhaps 
most enlightening were the observations by Roberts on a cohort of 224 randomly 
selected professional boxers in which he reported that 17% displayed a “relatively 
stereotyped” clinical picture, comprising emotional lability, personality change, 
memory impairment and dementia, as well as pyramidal and extrapyramidal 
dysfunction and cerebellar impairment (37). More recent descriptions in former non-
boxer athletes (American football, ice hockey, rugby) and military personnel report 
similar neuropsychiatric and behavioural problems, whilst expanding this to include 
aggression, poor judgment, depression, suicidal ideation and, in some instances, 
suicide (17, 38-41). Of note, these more recent case series in non-boxer athletes 
perhaps report less prevalent motor symptoms than earlier reports of former boxers. 
 
Studies reporting on dementia following moderate or severe sTBI typically describe 
the associated clinical syndrome as Alzheimer’s disease (AD) in type (27-31, 33), 
with only occasional studies formally recording clinical diagnosis based on validated 
consensus criteria (27-35). Notably, neuropathological confirmation that the 
pathology after sTBI conforms to AD in these reports is lacking. Certainly, there are 
no suitably designed, robust studies in the current era of understanding of the 
neuropathology of CTE confirming post-sTBI dementia is AD. In that regard, in 
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contrast to patients with AD and no history of TBI, dementia in association with sTBI 
is reported to feature prominent motor and neuropsychiatric symptoms, including 
depression and suicide (42, 43). As such, where evaluated in detail, the clinical 
syndrome of neurodegeneration following sTBI echoes rTBI, and appears distinct 
from AD. Thus, the traditional view permeating the literature that sTBI is specifically 
associated with the development of AD (44, 45)  appears speculative, at best, and 
without confirmatory neuropathology.  
 
CTE: a spectrum of neuropathology with TBI survival 
Though Martland called for neuropathology attention to describe the pathology of DP 
in his original publication in 1928, it took until 1954 for the first formal account of the 
neuropathology of the brain of a former boxer to be described (46). Thereafter 
several isolated case reports appeared in the following decades (9, 47-51), 
preceding the landmark observations of Prof JAN Corsellis on his neuropathological 
findings in a series of 15 former amateur and professional boxers (52). While further 
studies on the material from this unique cohort followed, added to by many more 
studies in both boxers and, more recently, non-boxer athletes, this original 
publication remains informative. Of note, the picture emerging from these original 
studies and the observations since is of a complex of pathologies following exposure 
to TBI, whether repetitive or single, that might best be regarded as a ‘polypathology’. 
However, though increasing reports on the pathology of CTE are emerging, the often 
limited case numbers, bias in case selection, differences in methodologies and lack 
of matched control observations creates challenges in identifying informative 
pathology and in permitting comparative observations between rTBI and sTBI. The 
following account reviews current understanding of the pathology of CTE, with 
observations on priority areas for attention in future studies. 
 
Macroscopic neuropathology 
A common observation in early cases reports in boxers is a degree of atrophy of the 
cerebral hemispheres (9, 17, 46-49, 51-57) and cerebellum (51, 60), the former  
often showing preferential frontal (9, 48, 50, 57, 58) and temporal lobe (58, 59) 
involvement,. In contrast, more recent reports on CTE in non-boxer athletes 
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document relatively mild global atrophy, with reduction in brain weight as a less 
consistent observation (11, 13-17, 39). Nevertheless a pattern of albeit relatively 
non-specific macroscopic features is emerging in studies on CTE in individuals 
exposed to rTBI encompassing atrophy of the mammillary bodies, a mild degree of 
ventricular enlargement (perhaps preferentially third ventricle) pallor of the substantia 
nigra and thinning of the corpus callosum (46-49, 51-53, 56, 57, 59). In contrast to 
these observations in rTBI, formal reports of brain atrophy from autopsy 
examinations following survival in sTBI are lacking. Notwithstanding this, generalized 
brain atrophy following sTBI is recognised, both at autopsy and in imaging studies, 
with the latter suggesting this atrophy continues beyond the acute phase into longer 
term survival (61-65). Further, as in rTBI, autopsy studies report notable thinning of 
the corpus callosum in a proportion of sTBI survivors a year or more from injury (23).  
 
Beyond evidence of cerebral atrophy, a feature described in a majority of cases 
following exposure to rTBI is abnormalities of the septum pellucidum, in particular 
cavum septum pellucidum (CSP), septal fenestration or, in occasional cases, 
complete absence of the septum (9, 11, 13, 14, 16, 17, 46-51, 53-57, 59, 60, 66-69). 
Though CSP is reported in up to a third of subjects in population studies as a 
‘normal’ finding (52, 70-73), evidence suggests both higher prevalence and greater 
extent of CSP in those exposed to rTBI (52). Further, imaging studies have 
confirmed CSP in vivo in boxers, with evidence in longitudinal studies supporting 
CSP as an acquired and evolving pathology (9, 50, 74, 75).  In contrast to 
experience in rTBI, to date, CSP has not been documented as a specific feature in 
late survivors of sTBI. 
 
Microscopic neuropathology 
To date, some 150 or so cases have been reported describing the neuropathology of 
those exposed to rTBI from a range of sports including boxing (22, 46, 52), American 
football, ice hockey, wrestling, soccer and rugby union (11, 13-20, 40, 41) and in 
military personnel (12, 19, 20) together with sporadic cases exposed to rTBI in other 
circumstances, including domestic abuse (60, 69, 76) and an approximately 40 
further cases reporting the pathology of survival from sTBI (21, 23, 77). However, 
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whilst relatively small numbers of cases have been recorded in the literature, it 
should be noted this does not represent the entire world’s incidence of CTE in the 
period from the first clinical description of Martland or the first pathology account in 
the 1950s. Instead, this represents recognised cases coming to autopsy, with 
undoubted, considerably higher numbers either clinically diagnosed as an alternate 
dementia, such as AD, or not recognised as CTE on neuropathology assessment at 
autopsy. Notably, to date, the pathology of CTE has only been recognised in 
circumstances where there has been exposure to brain injury, with this pathology 
featuring a range of abnormalities including pathologies in tau, amyloid beta, TDP-
43, neuroinflammation, axonal degeneration, white matter degradation and neuronal 
loss (21).  
 
Tau 
Under the high strain rates encountered in TBI, mechanical breaking of axonal 
microtubules occurs leading to transport interruption as a component of diffuse 
axonal injury (DAI)(78-80)(Figure 1). This vulnerability of axons to mechanical 
loading arises as a result of their unique viscoelastic properties, in turn thought to 
derive from the biophysical properties of the microtubule associated protein tau (80). 
Nevertheless, to date, examination of autopsy acquired tissue from patients dying in 
the acute phase post sTBI (up to 4 weeks survival) has reported no evidence of 
immediate tau pathology (81). In contrast, where sought, abnormal accumulation of 
hyperphosphorylated tau is a constant in reported CTE  cases (22) and in a 
proportion of patients dying a year or more from sTBI (21). Though deposition of tau 
is a feature of a number of neurodegenerative pathologies and can be observed in 
‘normal’ ageing, the pattern and distribution of tau pathology in CTE is sufficiently 
distinct as to be proposed as pathognomonic. Specifically, whether in material from 
survivors of rTBI or sTBI this pathology is characterised by accumulation of 
abnormal, hyperphosphorylated tau in both neurons and glia, showing a distinct 
perivascular accentuation and preferential involvement towards the depths of sulci in 
the neocortical grey matter (11, 17-19, 39, 40, 67, 82) (Figure 2). Typically, there is 
an irregular, ‘patchy’ involvement within and between involved cortical areas (17, 39, 
40, 82). This pattern, originally observed by Geddes and colleagues in their 
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description of tau pathology in boxers (67, 82), has since been confirmed and refined 
in subsequent case series in both rTBI and sTBI such that it’s appearance might be 
considered as defining CTE, in the correct clinical context.  
 
Remarkably there remain just two cases, former boxers, in which biochemical 
characterisation of tau in CTE has been performed (55). In both cases the 
hyperphosphorylated tau of CTE was indistinguishable from that in AD. Optimally 
assessed using immunostains for hyperphosphorylated tau (AT8, CP-13, PHF-1), 
the neuronal tau pathologies appear as typical neurofibrillary tangles (NFT) and 
pretangles which, beyond the perivascular accentuation and preferential involvement 
towards the depths of sulci, often show a distribution to superficial cortical layers 
(layers II/III) (39), compared to the involvement of deeper cortical layers more typical 
of AD. In the hippocampus, CTE is noted for preferential involvement of sector CA2 
by NFTs and extracellular tangles, with NFTs and astroglial tau pathology (Figure 
3a). Also a feature in the hypothalamic region, in particular the mammillary bodies 
(39). Beyond these regions, there may be frequent involvement of deep grey nuclei 
and brainstem as nucleus basalis of Meynert, substantia nigra (Figure 3b), locus 
coeruleus, raphe nuclei and tectum. In contrast, the dorsum striatum (caudate and 
putamen) appears relatively spared, as too are the cerebellar dentate nuclei. In 
addition to neuronal tangle and pretangle pathologies, frequent, perhaps distinctive 
‘grain-like’ tau-immunoreactive profiles and neurites are often present in affected 
neuropil. In addition, tau-immunoreactive axonal profiles are often observed in 
subcortical and midline white matter (Figure 3c,d). Finally, glial pathology is 
commonly observed as tau-immunoreactive thorn-shaped astrocytes located in 
subpial and perivascular locations in the neocortex and subependymally (39). 
  
In relation to rTBI, these tau pathologies have been documented in virtually all 
cases.  However, specifically for rTBI, there has been an unavoidable case selection 
bias and virtual absence of control, non-injured material in reports of CTE, rendering 
interpretations on incidence of this pathology meaningless in the context of exposure 
to repetitive mild injury. In contrast, in the single study looking at survivors of  sTBI, 
tau pathology was observed in up to 30% of patients a year or more following single 
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moderate to severe TBI, and in greater density and wider distribution than in age-
matched controls (21). However, as a retrospective, archive-based study no 
information on clinical status of these post-TBI, tau-positive patients was provided, 
hence the clinical significance of the autopsy identified pathology in this series 
remains uncertain.    
 
Regarding hierarchical evolution of tau pathologies in CTE, putative staging 
protocols have been suggested by authors reviewing material from athletes after 
rTBI, ranging from restricted, focal, cortical pathology (stage I) to more extensive, 
widespread cortical, hippocampal and brainstem involvement (stage IV) (39). 
However, validation of this proposed staging, in particular clinicopathological 
correlation, has yet to be completed. Of note, the single study on a limited number of 
sTBI cases reported a hierarchy similar to that for AD (21), though this might reflect 
more limited anatomical sampling in that cohort.  
 
Amyloid beta 
An early and consistent event in all severities of TBI, diffuse axonal injury results in 
cytoskeletal disruption with associated axonal transport interruption (61, 83-85). In 
common medicolegal practice DAI is sought by examining for evidence of transport 
interruption through the immunocytochemical demonstration of abnormal 
accumulation of beta amyloid precursor protein (APP) in injured axons (83, 86, 87). 
Normally transported by fast axonal transport, following TBI APP may be observed in 
damaged axons within hours of injury (Figure 6a)(Figure 1f). In addition, co-localizing 
with APP at these sites of injury are the enzymes presenelin-1 and β-site-APP-
cleaving enzyme required to cleave APP to amyloid-²  (A² ) (88-93). Thus, DAI 
creates an environment in which high concentrations of A²  protein may be generated 
following TBI (93) (Figure 1g). 
 
A hallmark pathology of AD, A²  plaques are identified in autopsy material from up to 
30% of patients dying acutely following single moderate to severe TBI and in excess 
of those seen in equivalent, non-injured, age matched controls (Figure 4a) (24, 25, 
94, 95). Further, A²  plaques can also be demonstrated in peri-contusional, 
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surgically-excised tissue from sTBI survivors (94). Typically, these acute plaques are 
diffuse in nature and similar to those of early stage AD. However, whereas plaques 
in AD are thought to develop slowly and occur predominantly in the elderly, TBI-
associated plaques are detectable within hours of injury and across a range of ages, 
including young adults. Notably, the appearance of these A²  plaques in the acute 
phase might represent not only excessive A²  genesis as a consequence of DAI, but 
also failure of normal A²  clearance pathways which become overwhelmed by excess 
parenchymal A²  production.  
 
In the months following injury, evidence suggests normal order in amyloid cycling 
might be restored, with these acute TBI plaques clearing (92). However, in 
observations on autopsy acquired material from survivors of a year or more from 
sTBI, amyloid plaques are again observed in considerably greater density and in 
wider distribution when compared to age matched, non-injured control material (21). 
Furthermore, whilst the acute plaques following TBI are typically diffuse in nature, 
those observed in survivors of a single moderate to severe TBI are more typically 
neuritic in type (21), thus more reminiscent of plaques in established AD (Figure 4b). 
 
In studies reviewing cases from the Corsellis collection, Roberts and colleagues 
observed the “occult aftermath of boxing”, referring to often abundant A²  plaques 
identified in autopsy acquired material from a cohort of 20 retired amateur and 
professional boxers, all but one case containing diffuse amyloid plaque pathology; 
the exception being a 22 year old former professional boxer with a three year career 
and only three professional fights (53). Of note, however, the remaining 19 cases 
ranged in age 53 to 83 (median 65) years, so arguably representing an ‘older’ cohort. 
All NFT positive cases in this cohort contained plaque. In more recent descriptions of 
CTE in former athletes A²  plaques are often reported as a less consistent 
observation (39). However, where documented, A²  plaque pathology is present in a 
majority of cases, the proportion increasing with advancing age (96). Hence the 
current recognition of tau pathologies leading to putative CTE diagnoses in 
comparably younger athletes might underlie the occasionally misreported assertion 
that amyloid pathologies are absent or rare in CTE, when indeed they appear a 
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frequent observation in older and, perhaps crucially, clinically confirmed cases.  In 
studies in rTBI material, these A²  plaques are almost invariably described as diffuse 
in nature (Figure 4c,d), in contrast to the more often neuritic plaque observed in long-
term survivors of sTBI. However, whilst much attention has focused on tau pathology 
in CTE in recent years, relatively little attention has focused on amyloid pathologies.  
 
Transactive response DNA binding protein 
The 43 kDa transactive response (TAR) DNA-binding protein (TDP-43) is a nuclear 
protein widely expressed throughout the body. However, under certain conditions 
TDP-43 may translocate from nucleus to cytoplasm forming polyubiquitinated and 
hyperphosphorylated pathological inclusion bodies; this abnormal TDP-43 
recognised as a major disease associated protein in a number of neurodegenerative 
conditions, including frontotemporal lobar dementia and amyotrophic lateral sclerosis 
(ALS) (97), and as a minor component of a variety of other conditions including 
Alzheimer’s disease, Parkinson’s disease  and a small proportion of ‘normal’ aged 
individuals (98-100). Of relevance, animal modelling studies in TBI suggest axonal 
injury might upregulate TDP-43 leading to its translocation from the nuclear to 
cytoplasmic compartment (101-103). With recovery, TDP-43 is restored to the 
nucleus, suggesting this redistribution represents some form of acute-phase 
response (101, 102). Thus there is potential that TBI induced axonal injury might 
influence neuronal TDP-43 processing.  
 
In limited observations in CTE following exposure to rTBI, including material from 
boxer and non-boxer athletes, neuronal cytoplasmic TDP-43 inclusions and 
distinctive ‘grain-like’ profiles in the surrounding neuropil have been documented in 
the hippocampus, temporal neocortex and amygdala in a majority of cases, where 
sought (18, 39, 77, 104). In a small proportion of these cases this TDP-43 pathology 
coincided with a clinical diagnosis of ALS, with the autopsy examination revealing 
features consistent with CTE (18). Based on these few observations, a diagnosis of 
chronic traumatic encephalomyopathy (CTEM) has been proposed (18), although 
whether with further case experience this putative diagnosis survives rigorous 
scrutiny remains to be explored. 
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In contrast to the similarities in pathologies in tau and A²  in survivors of rTBI and 
sTBI, there is a notable difference in TDP-43 pathology. Specifically, following 
survival from sTBI, whilst increased cytoplasmic immunoreactivity to ‘physiologic’, 
non-phosphorylated TDP-43 is observed in acute and late survivors (a year or more 
from injury), abnormally phosphorylated TDP-43 cytoplasmic inclusions are not 
reported in extent or distribution beyond that seen in non-injured control material 
(77). This intriguing apparent difference in pathologies between survivors of rTBI and 
sTBI might suggest a physiological role for TDP-43 in response to injury, which is 
somehow modified after exposure to repetitive brain injury precipitating cytoplasmic 
accumulation of hyperphosphorylated TDP-43. 
 
Neuroinflammation 
Neuroinflammation is increasingly regarded as an important facet of the pathology of 
a range of neurodegenerative disorders (105-107), with neuroinflammation in AD 
recognized as an early event in disease pathogenesis (108-111). Of note, as regards 
TBI, studies exploring serum or cerebrospinal fluid from patients surviving sTBI, 
report elevated pro-inflammatory cytokine levels correlating with poor 
neuropsychiatric outcome, including suicidal ideation (112-114).  
 
Immediately following injury, TBI induces a complex neuroinflammatory response, a 
consequence of blood brain barrier compromise and an acute phase inflammatory 
cell reaction featuring polymorphonuclear leucocytes, T-lymphocytes, macrophages 
and natural killer cells, together with activation of resident microglia in both humans 
and animal models (23, 115). Under normal circumstances it might be anticipated 
that this acute phase inflammation would resolve. However, in a proportion of 
survivors there is accumulating evidence that neuroinflammation persists beyond the 
acute phase (Figure 1j-l). Examination of autopsy acquired material from patients 
surviving sTBI reveals a remarkable and ongoing neuroinflammatory response in a 
proportion of survivors, even at decades’ survival following injury (Figure 5) (23). 
Intriguingly, whilst these autopsy observations noted florid neuroinflammation with 
numerous activated microglia in the corpus callosum, in vivo PET imaging studies 
with the ligand [11C]PK-11195 report no significant difference in binding in this 
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region, though do report a difference in binding over control patients in the thalamic 
region (116). As such, the possibility imaging studies might considerably 
underestimate or misrepresent neuroinflammation following TBI might be 
considered. Of note, evidence of persistent inflammation in these imaging studies 
correlated with clinical evidence of impaired cognition.  
  
In contrast to the limited, though detailed studies on neuroinflammation following 
sTBI, there has been comparatively little characterization of extent and distribution of 
the neuroinflammatory response following rTBI, although mention of 
neuroinflammation is made in several reports (47, 52, 56, 117). Further, numerous 
experimental models of rTBI have demonstrated persistent microglial activation after 
repetitive injury associated with ongoing degenerative pathology and evidence of 
cognitive deficit at up to 12 months post injury (118, 119). 
 
While neuroinflammation after TBI is increasingly documented, it remains unclear 
whether this neuroinflammation is primary, representing dysregulated inflammation 
driving late TBI pathology, or secondary, responding to ongoing post-TBI 
pathologies. However, data from experimental models suggest that the immediate 
microglial inflammatory response following TBI is of mixed reparative M2a 
(alternative) and neurotoxic M1 (classic) phenotype which might then be ‘switched’ to 
an M1 predominant phenotype in the chronic phase (115, 120, 121). Whether the 
microglial responses in human TBI, in particular the phenotypic profiles in early 
versus late survivors, mirror observations from animal studies has yet to be 
confirmed. 
 
Neuronal loss 
In studies on autopsy acquired tissue from patients sustaining single moderate to 
severe TBI a degree of acute phase neuronal loss has been documented (122, 123). 
Given the multiple acute pathologies of TBI, including diffuse axonal injury and the 
acute phase neuroinflammatory response, this neuronal loss is to be anticipated. 
However, there is evidence suggesting this neuronal loss might continue beyond the 
acute phase in a proportion of patients, with active degeneration of neurons via 
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programmed cell death observed in material from patients in the persistent 
vegetative state up to 1 year following single severe TBI, accompanied by evidence 
of continued reduction in hippocampal and thalamic neuronal densities (123-125). 
 
Neuronal loss is described in the majority of studies in boxers and non-boxers with 
CTE, involving the neocortex, substantia nigra, locus coeruleus and cerebellum (12-
16, 46, 48, 49, 51, 55, 57-60, 68, 126, 127). Varying degrees of cell loss have been 
described, from widespread and diffuse, to more “patchy” or selective changes.  Of 
note given reports of motor symptoms in CTE, in particular Parkinsonian symptoms, 
though there are reports of neuronal loss from the substantia nigra this is typically 
accompanied by nigral NFTs, with synuclein associated pathologies including Lewy 
bodies not a feature (13, 14, 46, 49, 52, 59). In contrast to rTBI, little is known about 
the vulnerability of the substantia nigra with survival from sTBI. 
 
White matter degradation and continued axonal degeneration 
As noted, a degree of DAI is regarded is a constant in all severities of TBI and is 
associated with cytoskeletal disruption and axonal transport interruption creating a 
milieu favoring rapid Aβ genesis in the acute setting (83-85, 88, 90, 91, 93). From the 
earliest accounts of axonal injury after TBI there has been an awareness that these 
white matter pathologies might continue beyond the immediate acute phase 
following injury (Figure 5). Specifically, using the Marchi technique, Sabina Strich 
demonstrated evidence of ongoing myelin degeneration at autopsy up to 15 months 
after survival from single severe TBI (128).  
 
As for progressive axonopathy after sTBI, a swine model of DAI demonstrated axons 
continue to degenerate months after injury (91), followed studies of patients surviving 
single moderate to severe TBI, showing evidence of ongoing axonal pathology in a 
proportion of survivors even decades after injury (23, 92) (Figure 1d). This 
progressive axonal pathology is characterized as morphologically abnormal, APP-
immunoreactive swollen axonal profiles in multiple regions (Figure 6).  These profiles 
are observed in isolation or as small clusters of somewhat granular axonal bulbs, 
indicative of disconnected axon terminals and evidence of ongoing axonal 
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degeneration with long-term survival. In addition, for human long-term survival, 
axonal loss in the corpus callosum was accompanied by remarkable thinning of the 
white matter and diminished or abnormal myelin staining, which coincided with 
amoeboid microglia containing myelin breakdown products, in keeping with ongoing 
myelin phagocytosis (23).  
 
In contrast to current experience in sTBI, accounts of white matter pathology after 
rTBI are limited. While early reports did not seek specific evidence of axonal 
pathology, more recent reports describe morphologically abnormal axonal profiles 
accumulating transport-interrupted proteins, including phosphorylated tau (19, 39), 
although without characterisation of extent and distribution or reference to controls or 
agonal state. As such, whilst these limited observations are noteworthy, formal 
characterisation of axonal pathology in rTBI remains to be pursed. Similarly, 
somewhat limited reports describe mixed observations regarding white matter 
pathology after rTBI, from foci of degeneration or rarefaction (12, 47, 56, 126), with 
reduced or patchy myelin staining (17, 47, 48, 52), to reports suggesting no evidence 
of demyelination (49).  
 
Genetics 
Despite axonal pathology and linked A²  production appearing ubiquitous after TBI, 
only 30% of patents develop A²  plaque in the acute phase following sTBI (24, 25, 
94, 95), with a similar proportion of long-term sTBI (21) and a majority of rTBI  
survivors (22, 96) depositing plaque. Among possible explanations for this variable 
response to injury, a potential genetic disposition is raised whereby some individuals 
cannot sufficiently clear A²  in the acute phase, whilst others slowly lose the battle to 
keep A²  deposition at bay over a period of years after TBI.  
 
APOE and TBI 
Possession of the ε4 allele of the APOE gene has long been associated with 
increased risk of AD (129, 130). Specifically, possession of the ε4 allele is 
associated with incidence of A²  pathologies in AD, and also with age-related A²  
deposition in cognitively intact individuals (131). In TBI there is considerable 
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evidence supporting an association between APOE genotype and prognosis 
following sTBI, with ε4 carriers demonstrating worse immediate and 6 month 
outcomes than non-ε4 carriers in a variety of clinical indices (132-141). Further, with 
longer survivals, the influence of the ε4 allele appears synergistic with TBI, with 
individuals possessing this allele at greater risk of dementia following injury than 
non-ε4 carriers (30, 32, 34, 142-144). This contrasts with longitudinal studies on 
outcome in late survivors of sTBI which, while confirming deterioration in measures 
of functional and cognitive outcomes over time, report no particular association with 
APOE genotype; although the age at follow-up in these studies might be argued as 
relatively young in comparison to studies reporting an association between TBI and 
dementia (47).  
 
Regarding mild TBI, thus far there is no convincing evidence of an association 
between APOE genotype and injury risk (145, 146). However, it should be noted that 
the number of injury episodes in these studies is small. In contrast, studies in longer 
term outcome from rTBI report possession of the ε4 allele to be associated with 
greater neurological impairment in high exposure boxers (those with greater than 12 
professional bouts) (147) and poorer cognitive performance in older professional 
American footballers (148). However, once again, the number of subjects in these 
studies is small. 
 
In relation to neuropathology, following single moderate to severe TBI, individuals 
possessing the ε4 allele demonstrate more severe contusional injury and show a 
trend towards more marked diffuse hypoxic brain injury (139). In addition, there is an 
increased incidence of amyloid plaque pathology in autopsy material from patients 
dying in the acute phase post sTBI compared to non-ε4 carriers (149). However, the 
association between APOE and late neuropathologies after sTBI remains unknown. 
Whilst the influence of APOE genotype on acute pathology after mild TBI remains 
unknown, studies on its influence on late pathology after exposure to rTBI are 
informative. Until recently, reports suggested no particular association between 
APOE genotype and CTE pathology as defined by characteristic tau deposition (11, 
39). However, in their more recent appraisal of their cohort of neuropathologically 
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confirmed CTE cases, specifically regarding Aβ pathologies, McKee and colleagues 
report a clear association between possession of the APOE-ε4 allele, Aβ pathologies 
and more advanced disease (96).  
 
Intriguingly, though the pathognomonic lesion of CTE is proposed to be tau, and 
considerable attention in current literature has focused on CTE as a ‘tauopathy’, the 
limited clinical reports on outcome from rTBI and on dementia after sTBI suggest 
possession of the APOE-ε4 allele as associated with increased risk of poor outcome. 
Further, in emerging pathology studies in CTE after rTBI, APOE-ε4 appears more 
closely associated with A²  pathologies than with tau. Together these observations 
suggest clinically relevant CTE might extend beyond being a pure tauopathy, with A²  
pathologies undoubtedly meriting closer attention.  
 
Neprilysin and TBI 
Neprilysin is recognised as the principal A²  degrading enzyme, with microsatellite 
polymorphism in the promoter region of the neprilysin gene (NEP) linked to amyloid 
pathologies, including AD and amyloid angiopathy (150-152).  In TBI a relationship 
between this GT repeat polymorphism and A²  plaque pathology has been 
demonstrated at up to 1 month following single moderate to severe TBI (153).  
Specifically, individuals carrying a longer repeat (greater than 41 total GT repeats) 
were at considerably greater risk of A²  plaque pathology after TBI than those with 
shorter repeat sequences. These findings implicate neprilysin in an important role in 
post-traumatic A²  metabolism and plaque formation. However, though an increase in 
intra-axonal neprilysin immunoreactivity has been observed in association with A²  
accumulation at up to 3 years following sTBI (92), the longer term association 
between NEP and neurodegenerative pathologies after TBI remains unknown. To 
date, no studies in neprilysin and rTBI outcome or pathology have been conducted.  
 
Conclusions 
Almost a century from the first clinical descriptions of the ‘punch drunk’ syndrome  
(6), several decades after the first comprehensive descriptions of an associated 
neuropathology (52), and with growing recognition in the past decade of the range of 
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circumstances in which the clinical syndrome and pathology arise, there can remain 
no doubt that in some individuals exposure to brain injury is associated with later 
development of a distinct neurodegenerative pathology. Thus far, though remarkably 
few cases have come to attention, this distinct neuropathology has only been 
described in autopsy material from individuals exposed to TBI, either as repetitive 
mild TBI or as single moderate to severe TBI.  Regarding the former, exposure to 
rTBI is most often described in relation to sports associated mild TBI, with the list of 
sports in which autopsy-proven CTE has been documented continuing to grow. As 
such, it is clear it is exposure to TBI that is associated with development of CTE, and 
not the sport or environment in which TBI is encountered.  
 
The association between exposure to TBI and increased risk of dementia is widely 
acknowledged. However, over the decades there has evolved an unsubstantiated 
view that dementia associated with exposure to rTBI represents CTE and is clinically 
and pathologically distinct from the dementia following exposure to sTBI, traditionally 
regarded as AD (44, 45). While studies in those exposed to rTBI distinguish their 
cohort from the outset as former boxers, American footballers or other athletes, and 
often are supported by neuropathological confirmation at autopsy, studies of 
dementia following sTBI are typically retrospective clinical reports with no autopsy 
confirmation of diagnosis; the diagnosis of AD in these studies, therefore, subject to 
errors in dementia diagnosis without autopsy validation. Of note, where careful 
clinical review in patients with AD is performed, the clinical syndrome in those 
exposed to sTBI is reported as distinct from that in patients with no exposure to TBI 
(42, 43). Further, though hampered by small case numbers, varied methodologies 
and limited cases reported, where suitable data is available, the pathologies of 
survival from sTBI and rTBI appear comparable, and distinct from existing 
descriptions of existing neurodegenerative pathologies, including AD (Table 1). 
 
Regarding this pathology, as more robust assessments emerge, it is clear the 
neuropathology of survival from TBI is complex and multi-faceted. An apparent 
constant is pathology in tau, with a relatively stereotyped pattern and distribution 
proposed as sufficiently distinctive as to be pathognomonic. However, while tau 
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pathologies have attracted attention, almost to the exclusion of wider pathologies, 
the complex of pathology after TBI extends to include pathologies in A²  and TDP-43, 
axonal degeneration, white matter degradation, neuronal loss and persistent 
neuroinflammation, at least. The significance of this complex of mixed pathologies to 
the clinical presentations of CTE remains to be established. Further, though there is 
emerging evidence on the potential contribution of genotype to the development of 
pathology after TBI, undoubtedly greater efforts to establish risk factors in 
development of CTE are required including, but not limited to, the contribution of 
severity and number of injuries and genotype and the influence of co-morbid 
pathologies.   
 
Undoubtedly, to advance understanding of the role that TBI might play in 
precipitating this distinct, complex, neurodegenerative pathology and gain insight into 
incidence, risk factors and risk modifiers, concerted efforts are required to establish 
collaborative programmes of research documenting outcome and, critically, 
neuropathology in survivors of TBI, whatever the source of injury. Through these 
studies insight might be provided to inform strategies for prevention and much 
needed, robust in vivo diagnostic strategies; CTE still remaining an autopsy defined 
diagnosis. However, despite remarkably few cases having been thoroughly 
evaluated neuropathologically, there can be no question that CTE is intimately 
associated with exposure to TBI. 
 
Summary Points 
1. Exposure to TBI is associated with increased risk of neurodegenerative 
disease 
2. The pathology of neurodegeneration after TBI, chronic traumatic 
encephalopathy (CTE), is a complex polypathology featuring tau as a 
constant, with abnormalities in Aβ and TDP-43, axonal degeneration, 
neuroinflammation, neuronal loss and white matter degradation also 
described 
3. It is exposure to TBI per se that is associated with risk of CTE, rather than the 
environment or circumstances of exposure  
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4. The clinical syndrome and neuropathology of survival from single moderate or 
severe TBI and repetitive mild TBI are comparable. Importantly, there is no 
neuropathological data to support neurodegeneration after sTBI is Alzheimer’s 
disease 
5. Global initiatives to support programmes of research in survivors of TBI 
directed to documenting outcome and, critically, the associated 
neuropathology are required. 
 
 
Acknowledgments 
This work was supported by National Institutes of Health grants NS038104 (DHS and WS), 
NS056202 and AG038911 (DHS), NHS Research Scotland Career Research Fellowship 
(WS) and the Sackler Institute (JH) 
 
 
23 
 
Table 1: Clinicopathological characteristics of CTE in patients exposed to 
repetitive mild TBI or surviving a year or more from a single moderate to 
severe TBI. 
Clinical history  rTBI sTBI 
Personality change  + + 
Impulsivity/ disinhibition  + + 
Depression, suicidality  + + 
Cognitive impairment  + + 
Gait disturbance  + + 
Parkinsonism  + ? 
Macroscopic Appearances    
Cerebral atrophy  + (+) 
Cerebellar atrophy  + ? 
Ventricular enlargement  + + 
Thinning of corpus callosum  + + 
Cavum septum pellucidum etc  + - 
Evidence of previous TBI  +/- +/- 
Microscopic Appearances    
Tau    
 Perivascular accentuation + + 
 Neurofibrillary tangles + + 
 Glial profiles + + 
 ‘Grain-like’ profiles + + 
 Sulcal depths + + 
 Superficial neocortical layers + + 
 Patchy distribution + ? 
 Hippocampal CA2 + ? 
 Hypothalamic + ? 
 Brainstem + ? 
 Axonal (+) (+) 
Amyloid beta    
 Diffuse plaque  + + 
 Neuritic plaque + + 
TDP-43    
 Hyperphosphorylated inclusions + - 
 Translocated nuclear to cytoplasm - + 
Neuroinflammation    
  (+) + 
Axonal degeneration    
  (+) + 
Neuronal loss    
  + + 
Myelin degradation    
  ? + 
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Key: rTBI, repetitive mild TBI; sTBI, single mild TBI; +, present; -, absent; +/-, may be either 
present or absent; (+), reported present but not formally assessed; ?, not known.   
 
 
Figure Legends 
 
Figure 1: Proposed evolution of axonal and microglial pathologies contributing 
to late neurodegeneration following TBI.  In the intact, uninjured axon (a) 
microtubules composed of tubulin dimers bound by tau protein (h) transport cargo 
along the axon, including APP and the enzymes responsible for its cleavage to 
Aβ (e). As a consequence of dynamic stretch during injury, there is a change in the 
physical properties of tau protein resulting in mechanical breaking of microtubules, 
tau liberation and its subsequent phosphorylation (j). At these sites of microtubule 
breakage transport interruption follows, with accumulation of transported cargo (f) 
resulting in axonal swelling (b), degeneration (c) and liberation of large pools of 
Aβ leading to plaque formation (g); a process which continues beyond the acute 
phase in a proportion of survivors (d). In parallel with this axonal pathology there is a 
notable neuroinflammatory response marked by quiescent, ramified microglia (j) 
becoming activated (k); these activated and amoeboid (l) microglia persisting beyond 
the acute phase in a proportion of survivors.  
 
Figure 2: Neocortical tau pathology in CTE. Tau immunoreactive profiles are 
distributed throughout the neocortex, though typically show preferential distribution 
towards the superficial neocortical layers and depths of sulci (a: 49M 12 months 
following single severe TBI), with a distinctive and characteristic perivascular 
accentuation of immunoreactive neurons and glia whether exposed to repetitive mild 
TBI (b: 56M former rugby player) or single moderate or severe TBI (c: 48M 3 years 
following single severe TBI). Accumulations of subpial thorn-shaped astrocytes may 
also be observed (d: 59M former soccer player). All sections stained for 
phosphorylated tau using antibody CP13 (courtesy Dr P Davies). 
 
 
Figure 3: Tau pathology in CTE. In addition to neocortical tau pathology, tau-
immunoreactive profiles are common in the hippocampus in CTE, with preferential 
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involvement of sector CA2 by NFTs and extracellular tangles and astroglial tau 
pathology (a: 59M former soccer player). Elsewhere, tau pathologies are described 
in   the deep grey nuclei and brainstem, where tau-immunoreactive substantia nigra 
neurons and neurites may be present, together with a degree of pigment 
incontinence (b: same case as in (a)). Scattered tau-immunoreactive axonal profiles 
are also common in subcortical and midline white matter (c: same case as (a); d: 
60M former boxer).  All sections stained for phosphorylated tau using antibody CP13 
(courtesy Dr P Davies). 
 
 
Figure 4: Aβ plaque pathologies following TBI. Diffuse Aβ plaques can be 
identified in autopsy and surgical material from approximately 30% of TBI patients in 
the acute phase post-injury (a: 51M 24hours following severe TBI). In the following 
weeks to months, these diffuse plaques resolve, only to re-emerge in around 30% of 
survivors a year or more from single moderate or severe TBI, as both neuritic and 
diffuse Aβ plaques (b: 55F 47 years survival from single severe TBI). Aβ plaques are 
also present in a majority of cases of CTE following exposure to repetitive mild TBI, 
typically, though not exclusively, diffuse in subtype (c: 60M former boxer; d: 59M 
former soccer player). All sections stained using antibody 6F3D, specific for the N-
terminal epitope of Aβ (Dako).  
 
 
Figure 5: Neuroinflammation and white matter degradation in the corpus 
callosum with survival following TBI. Approximately 30% of survivors a year or 
more from single moderate or severe TBI show evidence of white matter degradation 
as rarefaction in staining to Haematoxylin and eosin (d) when compared to non-
injured control material (a). Accompanying this is evidence of ongoing 
neuroinflammation in the form of numerous amoeboid, activated microglia (e) in 
contrast to quiescent, ramified microglia in non-injured controls (b). Staining for 
myelin with Luxol fast blue/ Cresyl violet demonstrates an associated loss of myelin 
with evidence of continued myelin degradation after trauma (f). (a)(b)(c) Sections 
from the corpus callosum of a 38M non-TBI control, cause of death sudden 
unexpected death in epilepsy. (d)(e)(f) Sections from the corpus callosum of a 56M 
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with a 3 year survival from single severe TBI. (b) And (e) stained for HLA-DP, DQ, 
DR using antibody CR3/43 (Dako) to reveal activated microglia. 
 
Figure 6: Axonal pathology in the corpus callosum with varying survival from 
TBI.  A constant in all severities of TBI is diffuse axonal injury (DAI) with associated 
axonal transport interruption.  In tissue sections DAI is revealed in sections stained 
for APP, and is detectable within an hours of injury as immunoreactive axonal 
profiles with varying abnormal morphologies (a: 18M 11hours survival from severe 
TBI). Beyond this acute phase axonal injury, evidence of ongoing axonal transport 
interruption marked by scattered, morphologically abnormal axons staining for APP 
remains present in survivors a year or more from single moderate or severe TBI (b: 
24M 8years survival from single severe TBI) and in material from individuals 
exposed to repetitive mild TBI (c: 59M former soccer player). All sections stained for 
an antibody to the N-terminal amino acids 66-81 of APP (Millipore).   
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